Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B
Open Access
- 2 October 2021
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 9 (10) , 2083
Abstract
The hepatitis B core-related antigen (HBcrAg) is an unprecedented novel HBV biomarker that plays an essential role in reflecting covalently closed circular DNA (cccDNA) in chronic hepatitis B (CHB) because its levels correlate with intrahepatic cccDNA and serum HBV DNA. In this review, we describe the clinical application of serum HBcrAg in CHB patients, with a particular focus on new therapies targeting intrahepatic HBV replication. (1) HBcrAg can be detected in clinical cases where serum HBV DNA is undetectable during anti-HBV therapy. (2) A highly sensitive HBcrAg assay (iTACT-HBcrAg) may be useful for monitoring HBV reactivation, as an alternative to HBV DNA. (3) Decreased HBcrAg levels have been significantly associated with promising outcomes in CHB patients, reducing the risk of progression or recurrence of hepatocellular carcinoma. Additionally, we focus on and discuss several drugs in development that target HBV replication, and monitoring HBcrAg may be useful for determining the therapeutic efficacies of such novel drugs. In conclusion, HBcrAg, especially when measured by the recently developed iTACT-HBcrAg assay, may be the most appropriate surrogate marker, over other HBV biomarkers, to predict disease progression and treatment response in CHB patients.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP21fk0310101, 21fk0310106)
- The Ministry of Education, Culture, Sports, Science, and Technology (19H03640, 21K07897)
This publication has 123 references indexed in Scilit:
- Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector NucleasesMolecular Therapy, 2013
- Medical Virology of Hepatitis B: how it began and where we are nowVirology Journal, 2013
- Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus InfectionMolecular Therapy, 2013
- Evolution and classification of the CRISPR–Cas systemsNature Reviews Microbiology, 2011
- Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxisHepatology International, 2011
- Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAsMolecular Therapy, 2010
- Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- Hepatitis B virus infectionThe Lancet, 2009
- Zinc Finger Proteins Designed To Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue CultureJournal of Virology, 2008
- Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B InfectionJournal of Clinical Microbiology, 2007